姓 名 | 付伟 | 性 别 | 女 |
职 称 | 教授 | 学 历 | 博士 |
电 话 | 021-51980096 | 传 真 | +86-21-51980096 |
电子邮件 | wfu@fudan.edu.cn | 个人主页 | |
通讯地址 | 上海市张衡路826号 | ||
教育经历
1990.07 – 1994.06 吉林大学化学系 学士
1996.09 – 2001.06 吉林大学理论化学研究所 博士
工作经历 1994.08 - 1996.08 吉林省石油化工研究院 助工
2001.07 - 2003.09 中科院上海药物所 博士后
2003.10 – 2006.09 美国休斯顿大学 博士后
2006.09 - 2006.12 巴塞罗那超级计算中心
2006.12 - 2012.11 复旦大学药学院 副研究员、硕士导师
2012.11 - 至今 复旦大学药学院 教授、博导
专家类别
NeoTrident第一代面向用户需求计算机辅助药物设计专业委员会专家
主要科研贡献
在中枢神经系统靶向单胺GPCR受体精神/神经类疾病药物分子设计与发现方面取得一系列重要进展,主要包括:
1. 发展了动态药物虚拟筛选新技术,提出了动态结合模式的新概念，设计合成了多巴胺受体、5-羟色胺受体为靶点的新结构类型高活性（nM量级）小分子化合物300余个, 初步揭示了这些小分子化合物对多巴胺受体及5-羟色胺受体的信号转导机制，建立了动态虚拟筛选方法。
2. 首次将分子模拟技术运用到脑靶向药物递送系统的设计和递送机制的研究中，揭示了脑靶向药物递送的分子机制，并运用该递药系统靶向递送自主研发的神经/精神类小分子入脑。
3. 培养博士后3人，博士生2人，硕士生7人，其中3名硕士获国家奖学金。
承担科研项目情况
1.国家自然科学基金面上项目，82073765，“二氢喹啉类RORγt反向激动剂银屑病治疗分子成药性研究”2021/01-2024/12, 55万元，在研，主持
2.国家自然科学基金面上项目，81773635，“芳基氨甲基-哌啶/四氢萘类μ/δ阿片受体双重功效镇痛分子成药性研究”2018/01-2021/12, 48万元，在研，主持
3.国家自然科学基金面上项目：新型D2 拮抗/5-HT1A 激动双重功效抗精神病药物分子设计、合成及药理研究，2012-2015年（81172919）；
4.国家自然科学基金面上项目新型D1，D3受体双靶点抗帕金森药物设计、合成及生物活性研究，2015.01-2018.12，（81473136）；主持
5. 国家自然科学基金青年基金项目1项：多巴胺D2受体拮抗类双重功效非经典安定剂的分子设计，2008.01-2010.12 (20702009)；主持
6.上海市科委生物医药领域科技支撑专项，20S11902400，“银屑病治疗分子E40的临床前研究”，2019/07-2021/09，2020.10.01-2023.9.30，50万元，主持；
7.上海市科委生物医药领域科技支撑基础重点项目，14431900500，“FW-2-115临床前研究”，2019/07-2021/09，60万元，主持，滚动支持
8.上海市科技行动计划（生物医药领域科技支撑）：以曲马多为先导的μ/δ双重功效阿片受体镇痛新药物分子筛选研究， 2014.7.1-2017.9.30（14431900500）；主持
9.教育部留学归国人员基金，多靶点作用的非经典安定剂分子设计与合成，2010.4-2010.4；主持
10. 美国Agilent公司大学资助项目，2008年8月-2009年8月，(0557)；主持
11. 国家博士点新教师基金，2008年1月-2010年12月，（20070246092）；主持
12. 上海市卫生局项目，阿片受体κ亚型选择性配基的分子设计、合成研究， 2008年1月-2009年12月(2007089)；主持
13.973计划,内源性代谢产物H2S对心脏细胞离子通道和血管新生通路的调控机制，2010.1-2014.8（2010CB912601），学术骨干
14. 863计划，基于活性小分子筛选与功能探索的新药研发信息整合系统（2009AA02Z308），一般学术骨干
获奖及荣誉
2020 《药物设计学》国家级线上线下一流课程
2019 复旦大学药学院本科教学先进个人
2018 复旦大学药学院院长奖
2014.08 中国药学会科技进步奖二等奖（第七完成人）
2012 《药物设计学》上海市精品课程团队
2005.02 美国德克萨斯州-英国联合研究组织第五届McLaughlin传染及免疫会议, 旅行奖，第一
2006.05 第十一届结构生物学年会最佳工作成果展示奖，(UTMB)，第一
2005.04 南德克萨斯大学夏季学士培训的“模范领导”称号
2003.08 上海市第九届科技论文大奖赛二等奖，第一
2013.05 – 现在 美国化学会会员
2012 – 2014 教育部留学归国人员基金评审启动专家
2013 – 现在 Elsevier旗下SCI期刊Chemical Biology & Drug Design杂志编辑
2015.01- 现在 《复旦学报》编辑
2012 – 现在 中国化学会会员
2012 – 现在 第一届面向用户需求的CADD产品专家
专著：
主编：
1. 付伟，叶德泳：《计算机辅助药物设计导论》，45万字，2017年，化工出版社，6月发行
参编：
2. 付伟，金国章，蒋华良：《脑内多巴胺》，第29章，2万字，2010年11月，上海科技出版社出版
教材：
参编：
叶德泳，付伟，《药物设计学》 ，（编写第3章--基于结构的药物设计，附录）编写8万字，2015年2月，高等教育出版社
授权专利：
1. 付伟；镇学初；刘慧芳；沈庆；杜鹏，吲哚苯酰胺类衍生物及其药物用途，专利号： ZL 2010 1 0254261.8
2. 付伟；李变，抑制Src非受体酪氨酸激酶的小分子化合物及其药物用途，专利号：ZL 2012 1 0426334.6
3. 付伟；镇学初；沈庆；熊子君；邓欣贤，4-（4-苯基哌嗪基）喹唑啉类衍生物药物用途，专利授权号：ZL 2011 1 0130565.8
4. 付伟；李变；古险峰，2-（喹唑啉-4- 氨基）-5- 噻唑甲酰胺类衍生物及其生物药物用途，ZL 2012 1 0426407.1
5. 付伟；杜鹏，吲哚哌嗪类衍生物的药物用途，专利授权号：ZL 2013 1 0051843.X
6. 付伟；杜鹏、镇学初，苯并氮杂唑类化合物制备方法及用途，专利授权号：ZL 2013 1 0071010.X
7. 付伟；刘景根；沈庆；李炜；徐学军，氨基甲基哌啶类衍生物及其制备方法和药物用途，专利授权号：ZL 2014 1 0625627.6，公开号：CN105646332
8. 付伟；沈庆；李炜；刘景根；徐学军，6-氨基甲基哌啶类衍生物及其制备方法和药物用途，专利授权号：ZL 2014 1 0182104.9，公开号：CN105017037
1.Xinyi Li，Li Xie，Xiangli Qu，Bangyi Zhao，Wei Fu*, Beili Wu*, Jian Wu*, GPR91, a critical signaling mechanism in modulating pathophysiologic processes in chronic illnesses The FASEB Journal. 2020;34:13091–13105.
2.Huoming Huang, Wenli Wang, Xuejun Xu, Chen Zhu, Yujun Wang, Jinggen Liu, Wei Li, Wei Fu*. Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic. European Journal of Medicinal Chemistry, 2020, 189: 112070.
3.Wenli Wang#, Lan Zheng#, Wei Li, Chen Zhu, Weiqing Peng, Bing Han,* and Wei Fu*. Design, Synthesis, and Structure–Activity Relationship Studies of Novel Indolyalkylpiperazine Derivatives as Selective 5-HT1A Receptor Agonists. Journal of Chemical Information and Modeling, 2020, 60(1): 235-248.
4.Nannan Sun#, Xiaojun Ma#, Kaifeng Zhou#, Chen Zhu, Zhonglian Cao, Yonghui Wang, Jun Xu*, Wei Fu*. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases[J]. European Journal of Medicinal Chemistry, 2020, 187: 111984.
5.Chen Zhu, Xinwei Li, Bangyi Zhao, Weiqing Peng, Wei Li, Wei Fu*.Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy[J]. European Journal of Medicinal Chemistry, 2020,193:112214.
6.Bangyi Zhao , Wei Li , Lijie Sun, Wei Fu*，The Use of Computational Approaches in the Discovery and Mechanism Study of Opioid Analgesics, Froteria in Chemistry, 2020, 8, 335
7.Xinyi Li, Li Xie, Xiangli Qu, Bangyi Zhao, Wei Fu*, Beili Wu*, Jian Wu*, GPR91, a Critical Signaling Mechanism in Modulating Pathophysiologic Processes in Chronic Illnesses，The FASEB Journal，2020，in press
8.陈莉莉，葛广波，荣艳，付伟，陈红专等．中药在新冠肺炎防治中的应用和研究进展［Ｊ］．上海中医药大学学报，2020，34（3）：1-8.
9.Li Xiao, Yujun Wang, Mumei Zhang, Weiwei Wu, Linghui Kong, Yan Ma, Xuejun Xu, Xiao Liu, Qian He, Yuanyuan Qian, Huijiao Sun, Haihao Wu, Cheng Lin, Huoming Huang, Rongrong Ye, Shuang Jiang, Ru-Feng Ye, Congmin Yuan, Shengyang Fang, Dengqi Xue, Xicheng Yang, Hao Chen, Yilin Zheng, Linqian Yu, Qiong Xie, Lan Zheng, Wei Fu, Wei Li*, Zhuibai Qiu, Jinggen Liu*, Liming Shao*. Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from N?Cyclopropylmethyl-7α-phenyl-6,14endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side E?ects Navigated by the Message-Address Concept. J. Med. Chem. 2019, 62, 11054?11070.
10.Shuai Gao*,et al. Wei Fu, Wei Lu*, Albumin tailoring fluorescence and photothermal conversion effect of near-infrared-II fluorophore for image-guided cancer photothermal therapy, Nature Communications, 2019,10,2206
11.Jiaojiao Xu, ... Wei Fu, Zeyu Xiao, Wei Lu* et al. , High Affinity of Chlorin e6 to Immunoglobulin G for Intraoperative Fluorescence Image-Guided Cancer Photodynamic and Checkpoint Blockade Therapy, ACS Nano, 2019, 13, 10242
12.Cheng Liu#, Congmin Yuan#, Pinwen Wu#, Chen Zhu, Hao Fang, Lili Wang, Wei Fu*. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2. Chem Biol Drug Des, 2018, 92, 1699-1707.
13.Hui-jiao Sun, Yu-hua Wang, Cong-min Yuan, Ling-hui Kong, Xue-jun Xu, Yu-jun Wang, Hai-hao Wu, Cheng Lin, Yuan-yuan Qian, Huo-ming Huang, Li Xiao, Xiao Liu, Qian He, Sheng-yang Fang, Deng-qi Xue, Xi-cheng Yang, Hao Chen, Yi-lin Zheng, Lan Zheng, Lin-qian Yu, Qiong Xie, Wei Fu, Wei Li*, Jing-gen Liu*, Zhui-bai Qiu, Li-ming Shao*. 7β-Methyl substituent is a structural locus associated with activity cli? for nepenthone analogues. Bioorganic & Medicinal Chemistry, 2018, 26, 4254–4263.
14.Congming Yuan#, Haihong Chen#, Nannan Sun#, Xiaojun Ma, Jun Xu and Wei Fu*. Molecular dynamics simulations on RORgammat: insights into its functional agonism and inverse agonism. Acta Pharmacol Sin, 2019, 40(11): 1480-1489.
15.Weili, et al. Wei Fu*, The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent delta-Opioid Agonistic Activities, ACS Chem. Neurosci., 2017, 8(4),766-776.
16.Peng Lian, Congmin Yuan, Qin Xu, Wei Fu*, Thermostability Mechanism for the Hyperthermophilicity of Extremophile Cellulase TmCel12A: Implied from Molecular Dynamics Simulation, J. Phys. Chem. B, 2016, 120, 7346
17.Jingye Zhang, Zining Liu, Peng Lian, Jun Qian, Xinwei Li, Lu Wang, Wei Fu,Liang Chen, Xunbin Wei*, Cong Li*. Selective imaging and cancer cell death via pH switchable near-infrared fluorescence and photothermal effects. Chem. Sci., 2016, 7, 5995–6005.
18.Qing Shen, Yuanyuan Qian, Xuejun Xu, Wei Li*, Jinggen Liu*, Wei Fu*, Discovery of Potent and Selective δ OpioidAgonists Derived from Tramadol, ACS Med. Chem. Letter, 2016, 7 (4): 391–396
19.Wei Li, Li Zhang Lili Xu, Congmin Yuan, Peng Du, Jiaojiao Chen, Xuechu Zhen, Wei Fu*, Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy, Chem. Biol.& Drug Design, 2016, 88, 599
20.Peng Ji, Congmin Yuan, Shuhua Ma, Junchao Fan, Wei Fu*, Chunhua Qiao*, 4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway , Bioor. Med. Chem. 24 (2016) 6174–6182
21.Zhao Yuan, Fu Wei, Yu Zhengtian, 'Conformational Preferences of π-π Stacking Between Ligand and Protein, Analysis Derived from Crystal Structure Data Geometric Preference of π-π Interaction.', in Interdiscip Sci. (2015) 7(3): 211-20
22.Xiaoli Wei, Changyou Zhan, Qing Shen,Wei Fu, Cao Xie, Jie Gao, Chunmei Peng, Ping Zheng, and Weiyue Lu, D-Peptide Ligand of Nicotine Acetylcholine Receptors for Brain-Targeted Drug Delivery， Angew Chem. Int. Ed. 2015, 54: 3023-3027
23.Peng Lian, LinLang Li, Chuanrong Geng, Xuechu Zhen, Wei Fu*, Novel potent 5-HT1AR agonists discovery based on a dynamical binding mode strategy, J. Chem. Info. Modeling, 2015, 55(8): 1616-1627
24.Xinxian Deng, Lin Guo, Lili Xu, Xuechu Zhen, Kunqian Yu, Weili Zhao, Wei Fu*, Discovery of Novel Potent and Selective Ligands for 5-HT2A Receptor with Quinazoline Scaffold, 2015, Bioorganic & Medicinal Chemistry Letters, 2015, 25 (18): 3970-3974
25.Qing Shen, Yuanyuan Qian, Xuejun Xu, Wei Li*, Jinggen Liu*, Wei Fu*, Discovery of Potent and Selectiveδ OpioidAgonists Derived from Tramadol, 2015, ACS Med. Chem. Letter, 2015, in press
26.Qing Shen, Yuanyuan Qian, Xuejun Xu, Wei Li,*, Jinggen Liu,*, Wei Fu*, Design, synthesis and biological evaluation of N-phenylalkyl-substituted tramadol derivatives as novel μ opioid receptor ligands, Acta Pharmacologica Sinica, 2015, 36: 887-894
27.Peng Lian, Lili Xu1, Chuanrong Geng1, Yuanyuan Qian1, Wei Li*, Xuechu Zhen* and Wei Fu*, A Computational Perspective on Drug Discovery and Signal Transduction Mechanism of Dopamine and Serotonin Receptors in the Treatment of Schizophrenia. , Curr. Pharm. Biotech., 2014, 15, 916-926
28.Lili Xu, Shanglin Zhou, Kunqian Yu, Bo Gao,Hualiang Jiang,*Xuechu Zhen,*Wei Fu*,Molecular Modeling of the 3D Structure of 5-HT1AR: Discovery of Novel 5-HT1AR Agonists viaDynamic Pharmacophore-Based Virtual Screening, J. Chem. Info. Modeling, 2013, 53, 3202?3211
29.Zijun Xiong, Lili Xu, Lin Guo, Xuechu Zhen*, Wei Fu*, Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies Of 10-Amino-3-Methoxy-6,8,12,12a-Tetrahydro-5HThiazolo[4',5':4,5]Pyrido[2,1-A]Isoquinolin-2-Ols As Novel Dopamine D1 Receptor Inhibitors, VRI Biol. Med. Chem, 2013, 1, 38-50
30.Bian Li, Lili Xu, Qing Shen, Xianfeng Gu*, Wei Fu*, Discovery of Novel Small Molecule Src Kinase Inhibitors via a Kinase-focused Drug-likeness Rule and Structure-based Virtual Screening, Molecular Simulation, 2014, 40, 341-348
31.Bei-Bei Tao, Shu-Yuan Liu, Cai-Cai Zhang, Wei Fu, Wen-Jie Cai, Yi Wang, Qing Shen, Ming-Jie Wang,Ying Chen, Li-Jia Zhang, Yi-Zhun Zhu, and Yi-Chun Zhu*,VEGFR2 Functions As an H2S-Targeting Receptor Protein Kinase with Its Novel Cys1045–Cys1024 Disulfide Bond Serving As a Specific Molecular Switch for Hydrogen Sulfide Actions in Vascular Endothelial Cells, Antioxidants Redox Signaling, 2014，71，3219-3139 (IF: 8.5)
32.Yunguo Gong, Wei Fu*, Kaixian Chen*, Dopamine D1 receptor and serotonin 5-HT1A receptor agonist effects of the natural product (–)-stepholidine: molecular modelling and dynamics simulations, Molecular Simulation, 2012, 38(12),970-979
33.Du Peng,Lili Xu, Jiye Huang, Kunqian Yu, Rui Zhao, Bo Gao, Hualiang Jiang, Weili Zhao, Xuechu Zhen*,Wei Fu*，Design, Synthesis and Evaluation of Indolebutylaminesas a Novel Class of Selective Dopamine D3 Receptor Ligands, Chem Biol. Drug Design, 2013, 82, 326-335
34.Wei Li, Li-li Xu, Qiong Xie, Yan Chen, Mei-yan Lu, Bo Chao, Xing-hai Wang, Yun Tang, Zhui-bai Qiu, Wei Fu*, Choiwan Lau*, “Theoretical and NMR Investigations on the Conformations of (-)-Meptazinol Hydrochloride in Solution”, Molecular Simulation, 2013, 1-5
35.Bian Li; Wei Li; Peng Du; Kunqian Yu; Wei Fu*, Molecular Insights into the D1R Agonist and D2R/D3R Antagonist Effects of the Natural Product (-)-Stepholidine: Molecular Modeling and Dynamics Simulations, J. Phys. Chem. B, 2012, 116, 8121-8130
36.Changyou Zhan, Bian Li, Luojuan Hu, Xiaoli Wei, LinyinFeng, Wei Fu*, Weiyue Lu* ,Micelle-Based Brain-Targeted Drug Delivery Enabled by a Nicotine Acetylcholine Receptor Ligand, Angew. Chem. Int. Ed. 2011, 50, 5482-5485(hot paper, highlight by Science Business Exchange, IF: 12.73)
37.Huifang Liu, Jian Chen, Qing Shen, Wei Fu* and Wei Wu, Molecular Insights on the Cyclic Peptide Nanotube-Mediated Transportation of Antitumor Drug 5-Fluorouracil,Molecular Pharmaceutics, 2010,7 ( 6), 1985–1994(SCI, IF: 5.4)
38.Liu Hui-fang, Shen Qing, Zhang Jian, FuWei?, Evaluation of various inverse docking schemes in multiple targets identification, J Mol Graph Model. 2010,29 , 326–330(SCI, IF: 2.2)
39. Wei Fu, JianhuaShen, XiaominLuo, Weiliang Zhu, Jiagao Cheng, Kaixian Chen, Guozhang Jin and Hualiang Jiang, Dopamine D1 Receptor Agonist and D2 Receptor Antagonist Dual Effects of Natural Product (-)-Stepholidine (SPD): Molecular Modeling and Dynamics Simulations,Biophys. J. 2007, 93: 1431-1441 (SCI, IF: 4.6)
40. Wei Fu, Meng Cui, James M. Briggs, Xiaoqin Huang, Bing Xiong, Yingmin Zhang, XiaominLuo, JianhuaShen, RuyunJi, Hualiang Jiang, Kaixian Chen, Brownian Dynamics Simulations of the Recognition of the Scorpion Toxin Maurotoxin with the Voltage-gated Potassium Ion Channels, Biophys. J., 2002, 83 (5), 2370(SCI,IF: 4.6)
41.Kunqin Yu, Wei Fu, Hong Liu, Xiaomin Luo, Kaixian Chen, Jian Ding, Jianhua Shen, Hualiang Jian, Computational simulations of interactions of scorpion toxins with the voltage-gated potassium ion channel. Biophys J. 2004 Jun;86(6):3542-55.(IF: 4.6)
42.Du Lin, Fu Wei (co-first author), Li De-Hai, PanQiu-Ming, Zhu Tian-Jiao, Geng Mei-Yu, Gu, Qian-Qun, Unprecedented Citrinin Trimer Tricitinol B Functions as a Novel Topoisomerase IIα Inhibitor, J. Med. Chem., 2011, 54, 5796-5810, (co-first author，IF: 5.207 )
43.Xinxian Deng, Qing Shen, Lili Xu, Zijun Xiong, Weili Zhao, Xuechu Zhen, Wei Fu*, Discovery of a Novel Dopamine D3 Receptor Inhibitor, Chem. J. Chinese Univ.2011, 32(8): 1783-1788 (SCI)
44.Zijun Xiong, Peng Du, Bian Li, Lili Xu, Xuechu Zhen, Wei Fu*, Discovery of a Novel 5-HT2A Antagonist by Pharmacophore-Based Virtual Screening. Chemical Research in Chinese Universities, 2011，27(4), 655-660 (SCI)
45.SHEN Qing, LIU Hui-fang, LI Wei, FU Wei*, Modulated interaction of μ/δ opioid receptors and the drug discovery and design strategy, Chinese Pharmacological Bulletin, 2010，26：4-8
46.LIU Hui-Fang, FU Wei*, JIN Guozhang, Action mechanism of atypical antipsychotics and vista of drug discovery, Chinese Journal of Pharmacology and Toxicology, 2008, 22,(6):470-476
47.Wei Li , Yi-Min Tao, Yun Tang, Xue-Jun Xu, Jie Chen, Wei Fu, Xing-Hai Wang, Bo Chao, Wei Sheng, Qiong Xie, Zhui-Bai Qiu,*, Jing-Gen Liu, Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton, BMCL, 2010, 20: 418–421
48.Yaxue Zha, Xuefeng Lu, Chao-yie Yang, Zhimin Huang, Wei Fu, Tingjun Hou, and Jian Zhang, Computational Modeling Toward Understanding Agonist Binding on Dopamine 3, J. Chem. Inf. Model. 2010, 50, 1633–1643
49.Aviv Paz, Qiong Xie, Harry M. Greenblatt, Wei Fu, Yun Tang, Israel Silman, Zhuibai Qiu, and Joel L. Sussman，The Crystal Structure of a Complex of Acetylcholinesterase with a Bis-(#)-nor-meptazinol Derivative Reveals Disruption of the Catalytic Triad, J. Med. Chem.,2009, 52 (8), 2543-2549
50.Q. Xie, H. Wang, Z. Xia, M. Lu, W. Zhang, X. Wang, W. Fu, Y. Tang, W. Sheng, W. Li, W. Zhou, X. Zhu, Z. Qiu and H. Chen, J. Med. Chem.51 (2008), p. 2027
51.Xiaoqin Huang, Hong Liu, Meng Cui, Wei Fu, Kunqian Yu, Kaixian Chen, XiaominLuo, JianhuaShen and Hualiang Jiang, Simulating the Interactions of Toxins with K+ Channels Current Pharmaceutical Design, 2004, 10, 1057-1067
52.Meng Cui, JianhuaShenJ, James Briggs, Wei Fu, Hualiang Jiang, Chen K. Brownian dynamics simulations of the recognition of the scorpion toxin P05 with the small-conductance calcium-activated potassium channels. J Mol Biol. 2002, 318(2):417-28
53. Wei Fu, Ji-Kang Feng, Ge-Bo Pan, Xiang Zhang, Ai-Min Ren, Calculations on the Electronic Structures and Nonlinear Second-order Optical Susceptibilities of Spiroannelated Quinone-type Methanofullerenes, Theoretical Chemistry Accounts, 2001,106, 241-250
54. Wei Fu, Ji-Kang Feng, Calculations on the Electronic Structure and Nonlinear Second-order Susceptibilities of Fulleropyrrolidine/Tetrathiafulvalene(C60PY/TTF) Based on Donor-Bridge-Acceptor Dyads, Can. J. Chem, 2001, 79, 1366-1375
55. Wei Fu, Ji-Kang Feng, Ge-Bo Pan, Ai-Min Ren , “Theoretical study on the third-order nonlinear optical properties of a serials of derived 9,9’-spiro-bifluorenes”, Journal of Molecular Structure (Theochem), 2001, 545, 157-165
56. Wei Fu, JiKangFeng, AiMinRen, Yao-Xian Li, “Nonlinearity Enhancement by Proton Transfer: A new Strategy for the Design of Nonlinear Optical Materials. ACTA CHIMICA SINCA, 2001, 22(11): 1869-1872 (in chinese).
57. Wei Fu, JiKangFeng, KunQian Yu, AiMinRen, ChiaChung Sun, “Theoretical studies of molecules with NLO properties on push-pull multi-cycle electro-optical polymer intermediates including thiophene ring” Chinese Journal of Chemistry, 2000,18,820-827
58. Wei Fu,FENGJi-Kang，Yu Kun-Qian，REN Ai-Min，CUI Meng, LI Yao-Xian, SUN Chia-Chung “Theoretical study on second-order nonlinear optical properties of unsymmetricbis(phenylethynyl)benzene series derivatives” ，Chinese Journal of Chemistry, 2000,18,No.2, 175-181.
59. Wei Fu, JiKangFeng, AiMinRen, ChiaChung Sun, “Theoretical Study on The Device of Molecules with First Hyperpolarizabilities on a Serials of Babituric Acid and its Derivatives, Chinese Journal of Chemistry, 2000,21,1892-1895
60.FENG Ji-Kang, Wei Fu, CUI Meng, SU Zong-Min, REN Ai-Min, “Calculations on the Electronic Structure and Nonlinear Second-order Susceptibility of Fullerene/Ferrocene Based Donor-Bridge-Acceptor Dyads”, ACTA CHIMICA SINCA, 2000,58,1112-1119. (in chinese)
61. Wei Fu, FENG Ji-Kang,REN Ai-Min , CUI Meng , JIN Hong-Wei, WANG Jiang-Hong, SHEN Yu-Quan, “Theoretical studies of molecules with nonlinear optical third-order susceptibilities on pull-push multi-cycle electro-optical polymer intermediates including thiophene-ring” Chemical journal of Chinese universities, 2000,21(5),771-775
62. Wei Fu，FENG Ji-Kang， REN Ai-Min， SUN Xiu-Yun,JIN Hong-Wei, “Theoretical Study on Second-order Nonlinear Optical Properties of a Serial of Novel Push-pull PolycyclicConjugated Molecules” Chemical journal of Chinese universities, 2000,21(4),616-619
63. Wei Fu, FENG Ji-Kang， REN Ai-Min，CUI Meng, SUN Xiu-Yun, LI Yao-Xian, “A Theoretical Study on Nonlinear Second-order Optical Properties of p-Nitro bis(phenylethynyl) benzene series derivatives” Chemical journal of Chinese universities, 1999,20(9),1424-1428.
64. Wei Fu, FENG Ji-Kang， REN Ai-Min，CUI Meng, SUN Xiu-Yun, LI Yao-Xian, “A ZINDO-SOS Study on Nonlinear Second-order Optical Properties of UnsymmetricBis(phenylethynyl) benzenes Series Derivatives” ACTA CHIMICA SINCA, 1999,57,1075-1080. (in Chinese)
65. Wei Fu, FENG Ji-Kang, REN Ai-Min, SUN Xiu-Yun,JIN Hong-Wei, WANG Jiang-Hong , SHEN Yu-Quan, “Theoretical studies with nonlinear optical third-order susceptibilities and designment of molecules on some organic NLO materials” Chinese J. Struct. Chem. 2000,19(1)57-64
66.Li Yao-Xian, Liu Fu-An, Wei Fu, et al. “Synthesis N-C60 aniline by using micro irradtation” J. Mol. Science, 1995, 11(3), 4. (in Chinese)
67. Wei Fu, JikangFeng and Gebo Pan “Nonlinearity Enhancement by proton transfer: A new strategy for the design of nolinear optical materials, Chemical journal of Chinese universities, 2001,22(11),1869-1872 (in chinese)
68.Jianjun Liu, JikangFeng, Wei Fu, AiminRen, Guixia Liu, Potential energy Surface of 1CH2+N2O Reaction, Acta Phys. Chim, Sin., 2001, 17(7): 586-593 (in chinese)
